JP7617334B1 - レボドパ脂肪酸誘導体、その製剤、及びパーキンソン病の治療のためのそれらの使用 - Google Patents

レボドパ脂肪酸誘導体、その製剤、及びパーキンソン病の治療のためのそれらの使用 Download PDF

Info

Publication number
JP7617334B1
JP7617334B1 JP2024101091A JP2024101091A JP7617334B1 JP 7617334 B1 JP7617334 B1 JP 7617334B1 JP 2024101091 A JP2024101091 A JP 2024101091A JP 2024101091 A JP2024101091 A JP 2024101091A JP 7617334 B1 JP7617334 B1 JP 7617334B1
Authority
JP
Japan
Prior art keywords
levodopa
derivative
pharma
chch
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024101091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025013734A (ja
Inventor
パテル デベン
ケイ． ミシュラ マノイ
ラジャン シャルマ エイチ．
レディ ペッダレディ ガリ レーマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DYNAMIC BIOLOGICS INC.
Original Assignee
DYNAMIC BIOLOGICS INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DYNAMIC BIOLOGICS INC. filed Critical DYNAMIC BIOLOGICS INC.
Application granted granted Critical
Publication of JP7617334B1 publication Critical patent/JP7617334B1/ja
Publication of JP2025013734A publication Critical patent/JP2025013734A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2024101091A 2023-07-05 2024-06-24 レボドパ脂肪酸誘導体、その製剤、及びパーキンソン病の治療のためのそれらの使用 Active JP7617334B1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/218,372 US12036199B1 (en) 2023-07-05 2023-07-05 Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of Parkinson's disease
US18/218,372 2023-07-05

Publications (2)

Publication Number Publication Date
JP7617334B1 true JP7617334B1 (ja) 2025-01-17
JP2025013734A JP2025013734A (ja) 2025-01-27

Family

ID=91759631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024101091A Active JP7617334B1 (ja) 2023-07-05 2024-06-24 レボドパ脂肪酸誘導体、その製剤、及びパーキンソン病の治療のためのそれらの使用

Country Status (9)

Country Link
US (2) US12036199B1 (OSRAM)
EP (1) EP4595956A1 (OSRAM)
JP (1) JP7617334B1 (OSRAM)
KR (1) KR102846332B1 (OSRAM)
CN (1) CN119264002B (OSRAM)
AU (1) AU2024204581B2 (OSRAM)
CA (1) CA3244296C (OSRAM)
IL (1) IL325508A (OSRAM)
WO (1) WO2025010073A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120119464B (zh) * 2025-04-18 2025-12-05 浙江理工大学 一种自清洁型亲水聚四氟乙烯纤维膜的制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025385A1 (en) 2003-02-07 2006-02-02 Daphne Atlas L-DOPA amide derivatives and uses thereof
JP2016516018A (ja) 2013-03-15 2016-06-02 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH562199A5 (OSRAM) 1970-10-30 1975-05-30 Hoffmann La Roche
AT324316B (de) * 1973-06-27 1975-08-25 Lannacher Heilmittel Verfahren zur herstellung von neuen racemischen oder optisch aktiven phenylalaninestern
GB0715712D0 (en) * 2007-08-11 2007-09-19 Proximagen Ltd Amino acid derivatives
US8207369B2 (en) * 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2020166473A1 (ja) * 2019-02-12 2020-08-20 国立大学法人筑波大学 レボドパ誘導体及びその使用
JP7656340B2 (ja) * 2019-06-28 2025-04-03 ダイナミック バイオロジクス インコーポレイテッド レボドパポリマーコンジュゲート、その製剤、およびパーキンソン病の治療のためのそれらの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025385A1 (en) 2003-02-07 2006-02-02 Daphne Atlas L-DOPA amide derivatives and uses thereof
JP2016516018A (ja) 2013-03-15 2016-06-02 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物

Also Published As

Publication number Publication date
AU2024204581B2 (en) 2025-07-31
EP4595956A1 (en) 2025-08-06
US12036199B1 (en) 2024-07-16
CA3244296C (en) 2026-04-28
CA3244296A1 (OSRAM) 2026-04-24
US20250114319A1 (en) 2025-04-10
NZ812405A (en) 2025-07-25
AU2024204581A1 (en) 2025-01-23
CN119264002B (zh) 2025-10-17
KR20250008693A (ko) 2025-01-15
CN119264002A (zh) 2025-01-07
IL325508A (en) 2026-02-01
WO2025010073A1 (en) 2025-01-09
KR102846332B1 (ko) 2025-08-18
JP2025013734A (ja) 2025-01-27

Similar Documents

Publication Publication Date Title
JP4612923B2 (ja) 安定化された４−アミノ−３−置換−ブタン酸誘導体含有製剤およびその製造法
KR102209353B1 (ko) 파킨슨 병 치료 방법
US20170296491A1 (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
JPH06508135A (ja) 抗変性活性剤としての置換ｎ−カルボキシアルキルペプチジル誘導体
KR102846332B1 (ko) 레보도파 지방산 유도체, 이의 제형, 및 파킨슨병의 치료를 위한 이들의 사용
CN103228618B (zh) 新化合物及其医药用途
JP7656340B2 (ja) レボドパポリマーコンジュゲート、その製剤、およびパーキンソン病の治療のためのそれらの使用
US20200179521A1 (en) Compositions and methods relating to salts of specialized pro-resolving mediators
US20240207410A1 (en) Stabilized liquid compositions comprising a levodopa-tyrosine conjugate and uses thereof
CN1115145C (zh) 药理活性β－氨基酸的可耐受性的改进
US12533417B2 (en) L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders
AU2013216632B2 (en) Intravenous antiviral treatments
WO2020178810A1 (en) Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US20230248696A1 (en) Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
AU2016262644A1 (en) Intravenous antiviral treatments
JP2016529273A (ja) 新規薬物製剤
LU86350A1 (fr) Sels et compositions pharmaceutiques hydrosolubles a base d'aminoalcools

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240729

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617334

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150